Molecular alterations for targeted therapy in metastatic gynecologic cancer
- Prosjektnummer
- 911624
- Ansvarlig person
- Helga B Salvesen
- Institusjon
- Helse Bergen HF
- Prosjektkategori
- Forskningsprosjekt
- Helsekategori
- Cancer
- Forskningsaktivitet
- 5. Treatment Developement
Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era".
Gynecol Oncol 2015 Feb;136(2):224-9. Epub 2014 des 12
PMID: 25511159
Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients.
Oncotarget 2015 Jan 20;6(2):1327-39.
PMID: 25415225
Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk.
Hum Mol Genet 2015 Mar 1;24(5):1478-92. Epub 2014 nov 6
PMID: 25378557
Loss of progesterone receptor links to high proliferation and increases from primary to metastatic endometrial cancer lesions.
Eur J Cancer 2014 Nov;50(17):3003-10. Epub 2014 sep 30
PMID: 25281525
Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer.
Mol Cancer 2014;13():223. Epub 2014 sep 27
PMID: 25261936
Annexin-A2 as predictor biomarker of recurrent disease in endometrial cancer.
Int J Cancer 2014 Sep 13. Epub 2014 sep 13
PMID: 25219463
Molecular profiling in fresh tissue with high tumor cell content promotes enrichment for aggressive adenocarcinomas in cervix.
Pathol Res Pract 2014 Nov;210(11):774-8. Epub 2014 jul 22
PMID: 25123963
A novel wnt regulatory axis in endometrioid endometrial cancer.
Cancer Res 2014 Sep 15;74(18):5103-17. Epub 2014 aug 1
PMID: 25085246
Current status of molecular biomarkers in endometrial cancer.
Curr Oncol Rep 2014 Sep;16(9):403.
PMID: 25064587
Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations.
Gynecol Oncol 2014 Sep;134(3):599-606. Epub 2014 jul 1
PMID: 24995579
High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors.
Br J Cancer 2014 Jul 8;111(1):78-84. Epub 2014 mai 22
PMID: 24853175
Switch in FOXA1 status associates with endometrial cancer progression.
PLoS One 2014;9(5):e98069. Epub 2014 mai 21
PMID: 24849812
Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene.
Oncotarget 2014 Feb 28;5(4):1052-61.
PMID: 24658009
Stathmin protein level, a potential predictive marker for taxane treatment response in endometrial cancer.
PLoS One 2014;9(2):e90141. Epub 2014 feb 25
PMID: 24587245
Clinical value of DNA content assessment in endometrial cancer.
Cytometry B Clin Cytom 2014 May;86(3):154-63. Epub 2014 feb 14
PMID: 24532190
Growth differentiation factor-15 as biomarker in uterine sarcomas.
Int J Gynecol Cancer 2014 Feb;24(2):252-9.
PMID: 24401984
Landscape of genomic alterations in cervical carcinomas.
Nature 2014 Feb 20;506(7488):371-5. Epub 2013 des 25
PMID: 24390348
High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Gynecol Oncol 2013 Feb;128(2):327-34. Epub 2012 des 4
PMID: 23219661
Polymorphisms in inflammation pathway genes and endometrial cancer risk.
Cancer Epidemiol Biomarkers Prev 2013 Feb;22(2):216-23. Epub 2012 des 5
PMID: 23221126
Lack of estrogen receptor-a is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.
Clin Cancer Res 2013 Mar 1;19(5):1094-105. Epub 2013 jan 14
PMID: 23319822
Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers.
PLoS One 2013;8(2):e54873. Epub 2013 feb 5
PMID: 23393560
High phospho-Stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition.
Clin Cancer Res 2013 May 1;19(9):2331-41. Epub 2013 mar 28
PMID: 23538402
Increased WD-repeat containing protein 1 in interstitial fluid from ovarian carcinomas shown by comparative proteomic analysis of malignant and healthy gynecological tissue.
Biochim Biophys Acta 2013 Nov;1834(11):2347-59. Epub 2013 mai 21
PMID: 23707566
PI3K Pathway in Gynecologic Malignancies.
Am Soc Clin Oncol Educ Book 2013.
PMID: 23714506
GALR1 methylation in vaginal swabs is highly accurate in identifying women with endometrial cancer.
Int J Gynecol Cancer 2013 Jul;23(6):1050-5.
PMID: 23727823
Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence.
Eur Radiol 2013 Oct;23(10):2916-25. Epub 2013 jun 4
PMID: 23732687
Hormone receptor loss in endometrial carcinoma curettage predicts lymph node metastasis and poor outcome in prospective multicentre trial.
Eur J Cancer 2013 Nov;49(16):3431-41. Epub 2013 aug 8
PMID: 23932335
Preoperative anemia, leukocytosis and thrombocytosis identify aggressive endometrial carcinomas.
Gynecol Oncol 2013 Nov;131(2):410-5. Epub 2013 sep 1
PMID: 24004646
Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer.
Cancer 2014 Feb 15;120(4):603-10. Epub 2013 okt 25
PMID: 24166148
Gynecologic Cancer InterGroup (GCIG) endometrial cancer clinical trials planning meeting: taking endometrial cancer trials into the translational era.
Int J Gynecol Cancer 2013 Oct;23(8):1528-34.
PMID: 24257568
Role of DNA methylation and epigenetic silencing of HAND2 in endometrial cancer development.
PLoS Med 2013 Nov;10(11):e1001551. Epub 2013 nov 12
PMID: 24265601
Integrated genomic characterization of endometrial carcinoma.
Nature 2013 May 2;497(7447):67-73.
PMID: 23636398
KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer.
Br J Cancer 2012 Dec;107(12):1997-2004. Epub 2012 okt 25
PMID: 23099803
ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas.
Mod Pathol 2013 Mar;26(3):428-34. Epub 2012 okt 19
PMID: 23080032
A discordant histological risk classification in preoperative and operative biopsy in endometrial cancer is reflected in metastatic risk and prognosis.
Eur J Cancer 2013 Feb;49(3):625-32. Epub 2012 okt 1
PMID: 23036850
Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcome.
Clin Cancer Res 2012 Oct;18(20):5806-15. Epub 2012 aug 21
PMID: 22912389
Follow-up of gynecological cancer patients after treatment - the views of European experts in gynecologic oncology.
Acta Obstet Gynecol Scand 2012 Nov;91(11):1286-92. Epub 2012 sep 18
PMID: 22880840
Magnetic resonance imaging performs better than endocervical curettage for preoperative prediction of cervical stromal invasion in endometrial carcinomas.
Gynecol Oncol 2012 Sep;126(3):413-8. Epub 2012 mai 15
PMID: 22609110
Lipocalin 2 expression is associated with aggressive features of endometrial cancer.
BMC Cancer 2012;12():169. Epub 2012 mai 6
PMID: 22559235
MDM2 promoter SNP344T>A (rs1196333) status does not affect cancer risk.
PLoS One 2012;7(4):e36263. Epub 2012 apr 30
PMID: 22558411
Standard 1.5-T MRI of endometrial carcinomas: modest agreement between radiologists.
Eur Radiol 2012 Jul;22(7):1601-11. Epub 2012 mar 28
PMID: 22453859
Genome-wide association study identifies a possible susceptibility locus for endometrial cancer.
Cancer Epidemiol Biomarkers Prev 2012 Jun;21(6):980-7. Epub 2012 mar 16
PMID: 22426144
Loss of GPER identifies new targets for therapy among a subgroup of ERa-positive endometrial cancer patients with poor outcome.
Br J Cancer 2012 May;106(10):1682-8. Epub 2012 mar 13
PMID: 22415229
The dynamics and prognostic potential of DNA methylation changes at stem cell gene loci in women's cancer.
PLoS Genet 2012 Feb;8(2):e1002517. Epub 2012 feb 9
PMID: 22346766
Improved survival related to changes in endometrial cancer treatment, a 30-year population based perspective.
Gynecol Oncol 2012 May;125(2):381-7. Epub 2012 feb 1
PMID: 22307064
ESGO statement on the role of CA-125 measurement in follow-up of epithelial ovarian cancer.
Int J Gynecol Cancer 2012 Jan;22(1):175.
PMID: 22193647
Stratification based on high tumour cell content in fresh frozen tissue promotes selection of aggressive endometrial carcinomas.
Histopathology 2012 Feb;60(3):516-9. Epub 2011 des 14
PMID: 22168220
Staging of endometrial carcinomas with MRI using traditional and novel MRI techniques.
Clin Radiol 2012 Jan;67(1):2-12. Epub 2011 nov 25
PMID: 22119292
SNP285C modulates oestrogen receptor/Sp1 binding to the MDM2 promoter and reduces the risk of endometrial but not prostatic cancer.
Eur J Cancer 2012 Sep;48(13):1988-96. Epub 2011 nov 24
PMID: 22119201
Revision of FIGO surgical staging in 2009 for endometrial cancer validates to improve risk stratification.
Gynecol Oncol 2012 Apr;125(1):103-8. Epub 2011 nov 17
PMID: 22100838
Cancer antigen 125: lost to follow-up?: a European society of gynaecological oncology consensus statement.
Int J Gynecol Cancer 2012 Jan;22(1):170-4.
PMID: 21921803
Markers for individualised therapy in endometrial carcinoma.
Lancet Oncol 2012 Aug;13(8):e353-61.
PMID: 22846840
Evolution in endometrial cancer: evidence from an immunohistochemical study.
Int J Gynecol Cancer 2011 Feb;21(2):316-22.
PMID: 21734474
Training in bowel and upper abdominal surgery in gynaecological oncology: European Society of Gynecological Oncology (ESGO) Statement.
Int J Gynecol Cancer 2011 Oct;21(7):1264-5.
PMID: 21720255
Subspecialist training in surgical gynecologic oncology in the Nordic countries.
Acta Obstet Gynecol Scand 2011 Aug;90(8):917-20. Epub 2011 jun 16
PMID: 21564027
A new method for isolation of interstitial fluid from human solid tumors applied to proteomic analysis of ovarian carcinoma tissue.
PLoS One 2011;6(4):e19217. Epub 2011 apr 26
PMID: 21541282
Follow-up routines in gynecological cancer - time for a change?
Acta Obstet Gynecol Scand 2011 Jul;90(7):707-18. Epub 2011 apr 15
PMID: 21382018
High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer.
Br J Cancer 2011 Mar;104(6):921-6. Epub 2011 feb 22
PMID: 21343929
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.
Cancer Cell 2011 Feb;19(2):273-82.
PMID: 21316605
The role of adjuvant chemotherapy in surgical stages I-II serous and clear cell carcinomas and carcinosarcoma of the endometrium: a collaborative study.
Int J Gynecol Cancer 2011 Feb;21(2):332-6.
PMID: 21270614
Stathmin overexpression identifies high-risk patients and lymph node metastasis in endometrial cancer.
Clin Cancer Res 2011 May;17(10):3368-77. Epub 2011 jan 17
PMID: 21242118
Genome-wide association study identifies a common variant associated with risk of endometrial cancer.
Nat Genet 2011 May;43(5):451-4. Epub 2011 apr 17
PMID: 21499250
Gene expression patterns related to vascular invasion and aggressive features in endometrial cancer.
Am J Pathol 2011 Feb;178(2):861-71.
PMID: 21281818
Elevated plasma growth differentiation factor-15 correlates with lymph node metastases and poor survival in endometrial cancer.
Clin Cancer Res 2011 Jul;17(14):4825-33. Epub 2011 mai 26
PMID: 21616994
Use of preoperative biomarkers to oidentify high risk endometrial carcinoma patient
Textbook of Gyneacological Oncology, ESGO, 2011
The European Network of Translational Research in Gynaecological Oncology (ENTRIGO)
Textbook of Gyneacological Oncology, ESGO, 2011
Clinical and molecular markers in endometrial cancer.
- Disputert:
- januar 2014
- Hovedveileder:
- Helga Birgitte Salvesen
Endometrial carcinoma: a step closer to individualized therapy?
- Disputert:
- september 2013
- Hovedveileder:
- Helga Birgitte Salvesen
Mutations and gene amplifications in endometrial carcinomas.
- Disputert:
- september 2013
- Hovedveileder:
- Helga Birgitte Salvesen
The microenvironment in human ovarian carcinoma - characterization through proteomic analysis of tissue interstitial fluid
- Disputert:
- oktober 2013
- Hovedveileder:
- Helge Wiig
Endometrial carcinoma; can biomarkers aid in the prediction of aggressive disease?
- Disputert:
- mai 2012
- Hovedveileder:
- Helga Salvesen
PhD
- Disputert:
- juni 2011
- Hovedveileder:
- Lars A Akslen
- Anne Margrete Øyan Prosjektdeltaker
- Karl-Henning Kalland Prosjektdeltaker
- Lars A. Akslen Prosjektdeltaker
- Bjørn Bertelsen Prosjektdeltaker
- Olav Vintermyr Prosjektdeltaker
- Line Bjørge Prosjektdeltaker
- Britt Edvardsen Prosjektdeltaker
- Kanthida Kusonmano Prosjektdeltaker
- Maria B Ræder Postdoktor
- Even Birkeland Ph.d.-kandidat
- Elisabeth Wik Ph.d.-kandidat
- Ellen Valen Prosjektdeltaker
- Jenny Hild Aase Husby Ph.d.-kandidat
- Frederik Holst Postdoktor
- Therese Bredholt Postdoktor
- Ingvild Løberg Tangen Ph.d.-kandidat
- Anna Berg Ph.d.-kandidat
- Mari Kyllesø Halle Ph.d.-kandidat
- Camilla Krakstad Postdoktor
- Erling Andre Høivik Postdoktor
- Ingunn Marie Stefansson Postdoktor
- Jone Trovik Postdoktor
- Ingfrid S Haldorsen Prosjektdeltaker
- Henrica Maria Johanna Werner Ph.d.-kandidat
- Kathrine Woie Prosjektdeltaker
- Hilde Renate H Engerud Prosjektdeltaker
- Siv Mjøs Prosjektdeltaker
- Karen Klepsland Mauland Prosjektdeltaker
- Helga Birgitte Salvesen Prosjektleder
- Kanthida Kusonmano Prosjektdeltaker
- Kadri Madissoo Prosjektdeltaker
- Hanne Haslene-Hox Ph.d.-kandidat
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til Faglig rapportering, Helse Vest